Lilly pulls Xigris off market after sepsis drug fails study
Eli Lilly and Co. said it will pull its Xigris sepsis drug from all markets after the treatment failed to reduce mortality in a study. The withdrawal may cost Lilly $75 million to $95 million in the fourth quarter.